- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Early response to Saxenda predicts improvements in weight loss
15 September 2015 • Author: Victoria White
New data from a post-hoc analysis of the Phase 3a SCALE clinical development programme were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting.
The data demonstrated that ‘early responders’ in the SCALE Obesity and Prediabetes and SCALE Diabetes trials who lost at least 5% of their body weight after completing 16 weeks of Novo Nordisk‘s Saxenda treatment had greater weight loss after completing 56 weeks, compared with ‘early non-responders’ losing less than 5% body weight with Saxenda after completing 16 weeks.
“These data demonstrate the importance of identifying those adults who respond early to Saxenda,” said Professor Matthias Blüher, head of the obesity outpatient clinic at the University of Leipzig, Germany, and SCALE trial investigator. “Not only are these Saxenda early responders more likely to achieve greater weight loss over time, they are also more likely to experience greater improvements in cardiometabolic risk factors.”
After completing 16 weeks of the SCALE Obesity and Prediabetes trial, 67.5% of adults with obesity or who were overweight with weight-related comorbidities (excluding type 2 diabetes), were early responders to Saxenda and experienced an average weight loss of 11.5% after completing 56 weeks of treatment, compared with a weight loss of 3.8% for early non-responders.
Early responders demonstrated greater improvements in cardiometabolic risk factors
After completing 16 weeks of the SCALE Diabetes trial, 50.4% of adults with obesity or who were overweight and had type 2 diabetes, were early responders to Saxenda , with a mean weight loss of 9.3% after completing 56 weeks of treatment compared with a weight loss of 3.6% for early non-responders.
Across both trials, early responders demonstrated greater improvements in cardiometabolic risk factors, including blood pressure, cholesterol and triglycerides, compared to early non-responders.
Saxenda is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake. Like human GLP-1, Saxenda regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake. As with other GLP-1 receptor agonists, Saxenda stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner. These effects can lead to a reduction of fasting and post-prandial blood glucose.
Saxenda was granted European marketing authorisation in March by the European Commission (EC). It was approved by the FDA in December last year and Health Canada in February.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics